

Boadie W Dunlop

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4623150/publications.pdf>

Version: 2024-02-01

167
papers

7,359
citations

81900

39
h-index

62596

80
g-index

177
all docs

177
docs citations

177
times ranked

9463
citing authors

#	ARTICLE	IF	CITATIONS
1	Combinatorial pharmacogenomic algorithm is predictive of sertraline metabolism in patients with major depressive disorder. <i>Psychiatry Research</i> , 2022, 308, 114354.	3.3	4
2	The relations between C-reactive protein and trauma exposure, PTSD and depression symptoms, and PTSD psychotherapy treatment response in treatment seeking veterans and service members. <i>Brain, Behavior, and Immunity</i> , 2022, 101, 84-92.	4.1	9
3	Metabolomic and inflammatory signatures of symptom dimensions in major depression. <i>Brain, Behavior, and Immunity</i> , 2022, 102, 42-52.	4.1	33
4	A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults. <i>Journal of Psychopharmacology</i> , 2022, 36, 368-377.	4.0	19
5	Genomics-based identification of a potential causal role for acylcarnitine metabolism in depression. <i>Journal of Affective Disorders</i> , 2022, 307, 254-263.	4.1	10
6	Making Sense of the Matrix: A Qualitative Assessment and Commentary on Connecting Psychiatric Symptom Scale Items to the Research Domain Criteria (RDoC).. <i>Innovations in Clinical Neuroscience</i> , 2022, 19, 26-32.	0.1	3
7	ERICH3: vesicular association and antidepressant treatment response. <i>Molecular Psychiatry</i> , 2021, 26, 2415-2428.	7.9	17
8	Dose- and time-dependent increase in circulating anti-inflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressive disorder and chronic inflammation. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2021, 164, 102219.	2.2	37
9	Six versus twelve weeks of Swedish massage therapy for generalized anxiety disorder: Preliminary findings. <i>Complementary Therapies in Medicine</i> , 2021, 56, 102593.	2.7	9
10	Navigating the Novel Psychotropics. <i>Focus (American Psychiatric Publishing)</i> , 2021, 19, 1-2.	0.8	1
11	Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression. <i>Focus (American Psychiatric Publishing)</i> , 2021, 19, 76-85.	0.8	0
12	Single-cell molecular profiling of all three components of the HPA axis reveals adrenal ABCB1 as a regulator of stress adaptation. <i>Science Advances</i> , 2021, 7, .	10.3	42
13	Efficacy of Vortioxetine Monotherapy for Posttraumatic Stress Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 172-179.	1.4	5
14	Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depression. <i>Psychiatry Research</i> , 2021, 296, 113649.	3.3	8
15	Combined effects of genotype and childhood adversity shape variability of DNA methylation across age. <i>Translational Psychiatry</i> , 2021, 11, 88.	4.8	27
16	Dry Those Crying Eyes. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 295-303.	1.4	9
17	Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression. <i>Translational Psychiatry</i> , 2021, 11, 153.	4.8	46
18	Safety of Using a Combinatorial Pharmacogenomic Test for Patients with Major Depressive Disorder in the GUIDED trial. <i>CNS Spectrums</i> , 2021, 26, 169-170.	1.2	0

#	ARTICLE	IF	CITATIONS
19	Effects of Vortioxetine Versus Placebo on Cognition and Functional Capacity in Adults With Posttraumatic Stress Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2021, Publish Ahead of Print, 501-503.	1.4	3
20	Establishing Evidence for Clinical Utility of a Neuroimaging Biomarker in Major Depressive Disorder: Prospective Testing and Implementation Challenges. <i>Biological Psychiatry</i> , 2021, 90, 236-242.	1.3	13
21	Moving on With Monoamine Oxidase Inhibitors. <i>Focus (American Psychiatric Publishing)</i> , 2021, 19, 50-52.	0.8	4
22	An intensive outpatient program with prolonged exposure for veterans with posttraumatic stress disorder: Retention, predictors, and patterns of change.. <i>Psychological Services</i> , 2021, 18, 606-618.	1.5	22
23	Indoxyl sulfate, a gut microbiome-derived uremic toxin, is associated with psychic anxiety and its functional magnetic resonance imaging-based neurologic signature. <i>Scientific Reports</i> , 2021, 11, 21011.	3.3	37
24	Obesogenic Medications and Weight Gain Over 24 Weeks in Patients with Depression: Results from the GUIDED Study. <i>Psychopharmacology Bulletin</i> , 2021, 51, 8-30.	0.0	0
25	Treatment-Specific Hippocampal Subfield Volume Changes With Antidepressant Medication or Cognitive-Behavior Therapy in Treatment-Naïve Depression. <i>Frontiers in Psychiatry</i> , 2021, 12, 718539.	2.6	9
26	Psychophysiological treatment outcomes: Corticotropin-releasing factor type 1 receptor antagonist increases inhibition of fear-potentiated startle in PTSD patients. <i>Psychophysiology</i> , 2020, 57, e13356.	2.4	19
27	Investigation of MORC1 DNA methylation as biomarker of early life stress and depressive symptoms. <i>Journal of Psychiatric Research</i> , 2020, 120, 154-162.	3.1	9
28	Somatic symptoms in treatment-naïve Hispanic and non-Hispanic patients with major depression. <i>Depression and Anxiety</i> , 2020, 37, 156-165.	4.1	21
29	Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes. <i>Journal of Affective Disorders</i> , 2020, 264, 90-97.	4.1	36
30	A Virtual Standardized Patient-Based Assessment Tool to Evaluate Psychiatric Residents'™ Psychopharmacology Proficiency. <i>Academic Psychiatry</i> , 2020, 44, 693-700.	0.9	11
31	Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 933-945.	1.2	13
32	Psychotherapy or medication for depression? Using individual symptom meta-analyses to derive a Symptom-Oriented Therapy (SOt) metric for a personalised psychiatry. <i>BMC Medicine</i> , 2020, 18, 170.	5.5	21
33	Concordance between clinician-rated and patient reported outcome measures of depressive symptoms in treatment resistant depression. <i>Journal of Affective Disorders</i> , 2020, 266, 22-29.	4.1	22
34	150 HAM-D6 Outcomes in a Randomized, Controlled Trial Evaluating the Utility of Combinatorial Pharmacogenomics in Depression. <i>CNS Spectrums</i> , 2020, 25, 295-296.	1.2	0
35	Combinatorial Pharmacogenomic Algorithm is Predictive of Citalopram and Escitalopram Metabolism in Patients with Major Depressive Disorder. <i>Psychiatry Research</i> , 2020, 290, 113017.	3.3	18
36	Beyond the bins: interpreting and discussing pharmacogenomic reports with psychiatric patients. <i>Revista Brasileira De Psiquiatria</i> , 2020, 42, 111-112.	1.7	1

#	ARTICLE	IF	CITATIONS
37	Temporal Stability of Cognitive Functioning and Functional Capacity in Women with Posttraumatic Stress Disorder. <i>Archives of Clinical Neuropsychology</i> , 2019, 34, 539-547.	0.5	4
38	Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients. <i>Translational Psychiatry</i> , 2019, 9, 173.	4.8	53
39	Changes in trauma-potentiated startle, skin conductance, and heart rate within prolonged exposure therapy for PTSD in high and low treatment responders. <i>Journal of Anxiety Disorders</i> , 2019, 68, 102147.	3.2	38
40	Changes in Dosing and Dose Timing of D-Cycloserine Explain Its Apparent Declining Efficacy for Augmenting Exposure Therapy for Anxiety-related Disorders: An Individual Participant-data Meta-analysis. <i>Journal of Anxiety Disorders</i> , 2019, 68, 102149.	3.2	36
41	Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment. <i>Frontiers in Neuroscience</i> , 2019, 13, 926.	2.8	15
42	Response to: Goldberg et al. and Severance et al. Letters to the Editor: The clinical significance of improving remission over standard of care “The reality of treatment resistant-based therapies. <i>Journal of Psychiatric Research</i> , 2019, 114, 211-213.	3.1	1
43	The symptom-specific efficacy of antidepressant medication vs. cognitive behavioral therapy in the treatment of depression: results from an individual patient data meta-analysis. <i>World Psychiatry</i> , 2019, 18, 183-191.	10.4	68
44	Recall accuracy for the symptoms of a major depressive episode among clinical trial participants. <i>Journal of Psychiatric Research</i> , 2019, 116, 178-184.	3.1	14
45	49 Combinatorial Pharmacogenomics to Guide Treatment Selection for Major Depressive Disorder: A Large, Blinded, Randomized Controlled Trial. <i>CNS Spectrums</i> , 2019, 24, 202-203.	1.2	1
46	Moving pharmacoepigenetics tools for depression toward clinical use. <i>Journal of Affective Disorders</i> , 2019, 249, 336-346.	4.1	25
47	Benefits of Sequentially Adding Cognitive-Behavioral Therapy or Antidepressant Medication for Adults With Nonremitting Depression. <i>American Journal of Psychiatry</i> , 2019, 176, 275-286.	7.2	43
48	Impact of Pharmacogenomics on Clinical Outcomes for Patients Taking Medications With Gene-Drug Interactions in a Randomized Controlled Trial. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.2	45
49	Comparing sensitivity to change using the 6-item versus the 17-item Hamilton depression rating scale in the GUIDED randomized controlled trial. <i>BMC Psychiatry</i> , 2019, 19, 420.	2.6	18
50	Suicidal ideation and other persisting symptoms after CBT or antidepressant medication treatment for major depressive disorder. <i>Psychological Medicine</i> , 2019, 49, 1869-1878.	4.5	13
51	Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. <i>Journal of Psychiatric Research</i> , 2019, 111, 59-67.	3.1	197
52	The hypothalamic-pituitary-adrenal axis in PTSD: Pathophysiology and treatment interventions. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 89, 361-379.	4.8	137
53	Model structure for protocol adherence utilizing a manualized therapeutic massage intervention. <i>Journal of Complementary and Integrative Medicine</i> , 2019, 16, .	0.9	3
54	When translational neuroscience fails in the clinic: Dexamethasone prior to virtual reality exposure therapy increases drop-out rates. <i>Journal of Anxiety Disorders</i> , 2019, 61, 89-97.	3.2	37

#	ARTICLE	IF	CITATIONS
55	Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials. <i>Pharmacogenomics</i> , 2019, 20, 37-47.	1.3	126
56	Differential change on depressive symptom factors with antidepressant medication and cognitive behavior therapy for major depressive disorder. <i>Journal of Affective Disorders</i> , 2018, 229, 111-119.	4.1	9
57	Placebo Effects Across Self-Report, Clinician Rating, and Objective Performance Tasks Among Women With Post-Traumatic Stress Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 200-206.	1.4	13
58	Massage therapy decreases cancer-related fatigue: Results from a randomized early phase trial. <i>Cancer</i> , 2018, 124, 546-554.	4.1	58
59	Test-Retest Reliability of the SERT Imaging Agent [¹¹ C]-HOMADAM in Healthy Humans. <i>Journal of Nuclear Medicine</i> , 2018, 59, 315-319.	5.0	1
60	Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein. <i>American Journal of Psychiatry</i> , 2018, 175, 251-261.	7.2	39
61	Imaging the Future of Major Depression. <i>Focus (American Psychiatric Publishing)</i> , 2018, 16, 3s-3s.	0.8	0
62	DNA methylation levels are associated with CRF1 receptor antagonist treatment outcome in women with post-traumatic stress disorder. <i>Clinical Epigenetics</i> , 2018, 10, 136.	4.1	36
63	Response rate profiles for major depressive disorder: Characterizing early response and longitudinal nonresponse. <i>Depression and Anxiety</i> , 2018, 35, 992-1000.	4.1	23
64	Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools. <i>Pharmacogenomics Journal</i> , 2018, 18, 613-622.	2.0	80
65	More Research Needed on the Association Between Genotype and Antidepressant Response: Response to Fabbri et al.. <i>American Journal of Psychiatry</i> , 2018, 175, 576-577.	7.2	3
66	Mapping depression rating scale phenotypes onto research domain criteria (RDoC) to inform biological research in mood disorders. <i>Journal of Affective Disorders</i> , 2018, 238, 1-7.	4.1	28
67	Performance of the Adult ADHD Self-Report Scale-v1.1 in Adults with Major Depressive Disorder. <i>Behavioral Sciences (Basel, Switzerland)</i> , 2018, 8, 37.	2.1	23
68	Defective Inflammatory Pathways in Never-Treated Depressed Patients Are Associated with Poor Treatment Response. <i>Neuron</i> , 2018, 99, 914-924.e3.	8.1	153
69	Temporal Profiles and Dose-Responsiveness of Side Effects with Escitalopram and Duloxetine in Treatment-Naïve Depressed Adults. <i>Behavioral Sciences (Basel, Switzerland)</i> , 2018, 8, 64.	2.1	12
70	Follow-up of monotherapy remitters in the PRoDICT study: Maintenance treatment outcomes and clinical predictors of recurrence.. <i>Journal of Consulting and Clinical Psychology</i> , 2018, 86, 189-199.	2.0	15
71	The structure of personality disorders within a depressed sample: Implications for personalizing treatment. <i>Personalized Medicine in Psychiatry</i> , 2017, 1-2, 59-64.	0.1	3
72	D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders. <i>JAMA Psychiatry</i> , 2017, 74, 501.	11.0	236

#	ARTICLE	IF	CITATIONS
73	549. DNA Methylation Biomarkers and Treatment Effects of a Corticotropin Releasing Hormone Type 1 Receptor Antagonist in a Biologically-Defined Subset of PTSD-Patients. <i>Biological Psychiatry</i> , 2017, 81, S222.	1.3	1
74	Effects of Patient Preferences on Outcomes in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) Study. <i>American Journal of Psychiatry</i> , 2017, 174, 546-556.	7.2	107
75	Functional Connectivity of the Subcallosal Cingulate Cortex And Differential Outcomes to Treatment With Cognitive-Behavioral Therapy or Antidepressant Medication for Major Depressive Disorder. <i>American Journal of Psychiatry</i> , 2017, 174, 533-545.	7.2	268
76	Melancholic and atypical depression as predictor and moderator of outcome in cognitive behavior therapy and pharmacotherapy for adult depression. <i>Depression and Anxiety</i> , 2017, 34, 246-256.	4.1	23
77	525. The Temporal Stability of Cognitive Functioning and Functional Capacity in Women with PTSD. <i>Biological Psychiatry</i> , 2017, 81, S213.	1.3	0
78	688. The CRH-1 Receptor Antagonist Saga in Mood and Anxiety Disorders: The Good, the Bad and the Ugly. <i>Biological Psychiatry</i> , 2017, 81, S279.	1.3	1
79	597. Clinical Staging of Major Depression: Multimodal-Imaging Approach. <i>Biological Psychiatry</i> , 2017, 81, S241-S242.	1.3	0
80	Corticotropin-Releasing Factor Receptor 1 Antagonism Is Ineffective for Women With Posttraumatic Stress Disorder. <i>Biological Psychiatry</i> , 2017, 82, 866-874.	1.3	74
81	Reported maladaptive decision-making in unipolar and bipolar depression and its change with treatment. <i>Psychiatry Research</i> , 2017, 257, 386-392.	3.3	14
82	How Shall I Diagnose Thee? Let Me Count the Ways. <i>Biological Psychiatry</i> , 2017, 82, 306-308.	1.3	1
83	Assessing Residents'™ Confidence in the Context of Pharmacotherapy Competence. <i>Academic Psychiatry</i> , 2017, 41, 350-353.	0.9	10
84	Transdiagnostic Clinical Global Impression Scoring for Routine Clinical Settings. <i>Behavioral Sciences (Basel, Switzerland)</i> , 2017, 7, 40.	2.1	42
85	Surveying Psychiatrists'™ Psychopharmacology Practices Across Common Clinical Scenarios. <i>Focus (American Psychiatric Publishing)</i> , 2017, 15, 445-449.	0.8	1
86	Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA). <i>Psychopharmacology</i> , 2017, 234, 2883-2895.	3.1	65
87	Common genes associated with antidepressant response in mouse and man identify key role of glucocorticoid receptor sensitivity. <i>PLoS Biology</i> , 2017, 15, e2002690.	5.6	28
88	Pharmacogenetic Decision Support Tools: A Component of Precision Medicine for Psychiatry?. <i>Focus (American Psychiatric Publishing)</i> , 2017, 15, 3s-4s.	0.8	1
89	Neuroimaging Advances for Depression. <i>Cerebrum: the Dana Forum on Brain Science</i> , 2017, 2017, .	0.1	1
90	Evidence-Based Applications of Combination Psychotherapy and Pharmacotherapy for Depression. <i>Focus (American Psychiatric Publishing)</i> , 2016, 14, 156-173.	0.8	20

#	ARTICLE	IF	CITATIONS
91	Time-dependent effects of dexamethasone plasma concentrations on glucocorticoid receptor challenge tests. <i>Psychoneuroendocrinology</i> , 2016, 69, 161-171.	2.7	33
92	Divergent Outcomes in Cognitive-Behavioral Therapy and Pharmacotherapy for Adult Depression. <i>American Journal of Psychiatry</i> , 2016, 173, 481-490.	7.2	41
93	When Should a Patient Be Declared Recovered From a Major Depressive Episode?. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e1026-e1028.	2.2	4
94	Acute Swedish Massage Monotherapy Successfully Remediate Symptoms of Generalized Anxiety Disorder. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e883-e891.	2.2	31
95	Depression Worsening Associated With Lorcaserin. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 747-749.	1.4	4
96	Assessment of the Efficacy and Safety of BMS-820836 in Patients With Treatment-Resistant Major Depression. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 454-459.	1.4	9
97	Mediators of Sexual Functioning and Marital Quality in Chronically Depressed Adults with and Without a History of Childhood Sexual Abuse. <i>Journal of Sexual Medicine</i> , 2015, 12, 813-823.	0.6	29
98	Preliminary Findings Supporting Insula Metabolic Activity as a Predictor of Outcome to Psychotherapy and Medication Treatments for Depression. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2015, 27, 237-239.	1.8	37
99	Baseline Depression Severity as Moderator of Depression Outcomes Between Cognitive Behavioral Therapy vs Pharmacotherapy. <i>JAMA Psychiatry</i> , 2015, 72, 1102.	11.0	155
100	Prediction of treatment outcomes in major depressive disorder. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 669-672.	3.1	26
101	The Over-Under on the Misdiagnosis of Bipolar Disorder: A Systematic Review. <i>Current Psychiatry Reviews</i> , 2015, 11, 222-234.	0.9	2
102	Antidepressant Signal Detection in the Clinical Trials Vortex. <i>Journal of Clinical Psychiatry</i> , 2015, 76, e657-e659.	2.2	3
103	Reconciling Variable Findings of White Matter Integrity in Major Depressive Disorder. <i>Neuropsychopharmacology</i> , 2014, 39, 1332-1339.	5.4	57
104	A Randomized, Double-Blind Evaluation of α -Cycloserine or Alprazolam Combined With Virtual Reality Exposure Therapy for Posttraumatic Stress Disorder in Iraq and Afghanistan War Veterans. <i>American Journal of Psychiatry</i> , 2014, 171, 640-648.	7.2	354
105	GENDER AS PREDICTOR AND MODERATOR OF OUTCOME IN COGNITIVE BEHAVIOR THERAPY AND PHARMACOTHERAPY FOR ADULT DEPRESSION: AN α INDIVIDUAL PATIENT DATA α META-ANALYSIS. <i>Depression and Anxiety</i> , 2014, 31, 941-951.	4.1	122
106	Assessing Treatment-Resistant Posttraumatic Stress Disorder: The Emory Treatment Resistance Interview for PTSD (E-TRIP). <i>Behavioral Sciences (Basel, Switzerland)</i> , 2014, 4, 511-527.	2.1	40
107	How well do clinicians and patients agree on depression treatment outcomes? Implications for personalized medicine. <i>Human Psychopharmacology</i> , 2014, 29, 528-536.	1.5	11
108	ENHANCING HISPANIC PARTICIPATION IN MENTAL HEALTH CLINICAL RESEARCH: DEVELOPMENT OF A SPANISH-SPEAKING DEPRESSION RESEARCH SITE. <i>Depression and Anxiety</i> , 2014, 31, 258-267.	4.1	26

#	ARTICLE	IF	CITATIONS
109	Ziprasidone monotherapy is ineffective for bipolar-associated anxiety. <i>Evidence-Based Mental Health</i> , 2014, 17, 109-109.	4.5	0
110	Combination Psychotherapy and Antidepressant Medication Treatment for Depression: For Whom, When, and How. <i>Annual Review of Psychology</i> , 2014, 65, 267-300.	17.7	72
111	REVIEW OF NUTRITIONAL SUPPLEMENTS FOR THE TREATMENT OF BIPOLAR DEPRESSION. <i>Depression and Anxiety</i> , 2014, 31, 379-390.	4.1	16
112	Cognition, functional capacity, and self-reported disability in women with posttraumatic stress disorder: Examining the convergence of performance-based measures and self-reports. <i>Journal of Psychiatric Research</i> , 2014, 57, 51-57.	3.1	35
113	Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 240.	1.6	41
114	Pretreatment Brain States Identify Likely Nonresponse to Standard Treatments for Depression. <i>Biological Psychiatry</i> , 2014, 76, 527-535.	1.3	119
115	MicroRNA 135 Is Essential for Chronic Stress Resiliency, Antidepressant Efficacy, and Intact Serotonergic Activity. <i>Neuron</i> , 2014, 83, 344-360.	8.1	321
116	Cognitive Effects of Quetiapine XR in Patients With Euthymic Bipolar Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 383-385.	1.4	7
117	Neuroimaging-based biomarkers for treatment selection in major depressive disorder. <i>Dialogues in Clinical Neuroscience</i> , 2014, 16, 479-490.	3.7	103
118	Do alcohol use disorders destabilize the course of bipolar disorder?. <i>Journal of Affective Disorders</i> , 2013, 145, 1-10.	4.1	37
119	Toward a Neuroimaging Treatment Selection Biomarker for Major Depressive Disorder. <i>JAMA Psychiatry</i> , 2013, 70, 821.	11.0	455
120	A Simple Question Answered: Adding Moderate-Dosage Lithium Does Not Help Patients With Bipolar Disorder. <i>American Journal of Psychiatry</i> , 2013, 170, 9-11.	7.2	1
121	Posttraumatic Stress Disorder Increases Sensitivity to Long Term Losses among Patients with Major Depressive Disorder. <i>PLoS ONE</i> , 2013, 8, e78292.	2.5	29
122	Efficacy and Safety of Desvenlafaxine 50 mg/d in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 1010-1017.	2.2	49
123	Ten ways to improve the treatment of depression and anxiety in adults. <i>Mental Health in Family Medicine</i> , 2013, 10, 175-81.	0.2	2
124	US Psychiatric Residents'™ Treatment of Patients With Bipolar Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 231-236.	1.4	12
125	A Meta-analysis of Factors Impacting Detection of Antidepressant Efficacy in Clinical Trials: The Importance of Academic Sites. <i>Neuropsychopharmacology</i> , 2012, 37, 2830-2836.	5.4	43
126	Pharmacological Innovations for Posttraumatic Stress Disorder and Medication- Enhanced Psychotherapy. <i>Current Pharmaceutical Design</i> , 2012, 18, 5645-5658.	1.9	38

#	ARTICLE	IF	CITATIONS
127	The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorder. <i>Journal of Psychiatric Research</i> , 2012, 46, 1406-1413.	3.1	185
128	Predictors of remission in depression to individual and combined treatments (PReDICT): study protocol for a randomized controlled trial. <i>Trials</i> , 2012, 13, 106.	1.6	108
129	BDNF function as a potential mediator of bipolar disorder and post-traumatic stress disorder comorbidity. <i>Molecular Psychiatry</i> , 2012, 17, 22-35.	7.9	91
130	Pharmacology and neuroimaging of antidepressant action. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 106, 643-655.	1.8	0
131	Depression beliefs, treatment preference, and outcomes in a randomized trial for major depressive disorder. <i>Journal of Psychiatric Research</i> , 2012, 46, 375-381.	3.1	67
132	Recovery and subsequent recurrence in patients with recurrent major depressive disorder. <i>Journal of Psychiatric Research</i> , 2012, 46, 708-715.	3.1	14
133	Preconsent education about research processes improved African Americans' willingness to participate in clinical research. <i>Journal of Clinical Epidemiology</i> , 2011, 64, 872-877.	5.0	24
134	The effects of sertraline on psychopathic traits. <i>International Clinical Psychopharmacology</i> , 2011, 26, 329-337.	1.7	20
135	Symptomatic and Functional Improvement in Employed Depressed Patients. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 569-576.	1.4	71
136	Conceptualizing Treatment Nonadherence in Patients with Bipolar Disorder and PTSD. <i>CNS Spectrums</i> , 2011, 16, 11-20.	1.2	17
137	Will current socioeconomic trends produce a depressing future for men?. <i>British Journal of Psychiatry</i> , 2011, 198, 167-168.	2.8	13
138	Tolerability of the dexamethasone-corticotropin releasing hormone test in major depressive disorder. <i>Journal of Psychiatric Research</i> , 2011, 45, 24-28.	3.1	5
139	Concordance between clinician and patient ratings as predictors of response, remission, and recurrence in major depressive disorder. <i>Journal of Psychiatric Research</i> , 2011, 45, 96-103.	3.1	39
140	Public Health Consequences of State Immigration Laws. <i>Southern Medical Journal</i> , 2011, 104, 718-719.	0.7	9
141	Treating Nonspecific Anxiety and Anxiety Disorders in Patients With Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 81-90.	2.2	43
142	An Additional Consideration for Comparisons of Antidepressants Versus Placebo. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 641-642.	1.4	1
143	Survey of Investigators' Opinions on the Acceptability of Interactions With Patients Participating in Clinical Trials. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 323-327.	1.4	6
144	Should Sensitive Information From Clinical Trials Be Included in Electronic Medical Records?. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 685.	7.4	5

#	ARTICLE	IF	CITATIONS
145	Response to Treatment with Placebo, Medication or Psychotherapy in Severe Non- Psychotic Major Depressive Disorder. <i>Current Psychiatry Reviews</i> , 2010, 6, 28-45.	0.9	4
146	Test-retest reliability of the SERT imaging agent [11C]HOMADAM in healthy humans. <i>NeuroImage</i> , 2010, 52, S110.	4.2	0
147	Correlation between patient and clinician assessments of depression severity in the PREVENT study. <i>Psychiatry Research</i> , 2010, 177, 177-183.	3.3	40
148	Enhancing Informed Consent in Clinical Trials and Exploring Resistances to Disclosing Adverse Clinical Trial Results. <i>American Journal of Bioethics</i> , 2009, 9, 39-41.	0.9	4
149	A renewed, ethical defense of placebo-controlled trials of new treatments for major depression and anxiety disorders. <i>Journal of Medical Ethics</i> , 2009, 35, 384-389.	1.8	17
150	Exploratory structural equation modeling of resting-state fMRI: Applicability of group models to individual subjects. <i>NeuroImage</i> , 2009, 45, 778-787.	4.2	58
151	Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population. <i>International Clinical Psychopharmacology</i> , 2009, 24, 204-213.	1.7	29
152	Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study. <i>Psychopharmacology Bulletin</i> , 2009, 42, 5-20.	0.0	4
153	Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75-225 mg/day in patients with recurrent major depression: a secondary analysis of data from the PREVENT study. <i>International Clinical Psychopharmacology</i> , 2008, 23, 357-363.	1.7	15
154	Combination Treatment With Benzodiazepines and SSRIs for Comorbid Anxiety and Depression. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2008, 10, 222-228.	0.6	82
155	Exercise for depression: efficacy, safety and clinical trial implications. <i>Psychopharmacology Bulletin</i> , 2008, 41, 65-75.	0.0	2
156	Coadministration of Modafinil and a Selective Serotonin Reuptake Inhibitor From the Initiation of Treatment of Major Depressive Disorder With Fatigue and Sleepiness. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 614-619.	1.4	44
157	The Impact of HIPAA Authorization on Willingness to Participate in Clinical Research. <i>Annals of Epidemiology</i> , 2007, 17, 899-905.	1.9	29
158	Two years of maintenance treatment with venlafaxine xr 75-225 mg/d: Efficacy in patients with recurrent unipolar major depression. <i>European Psychiatry</i> , 2007, 22, S239-S240.	0.2	2
159	The Role of Dopamine in the Pathophysiology of Depression. <i>Archives of General Psychiatry</i> , 2007, 64, 327.	12.3	991
160	Use of Dialectical Behavior Therapy in Borderline Personality Disorder: A View From Residency. <i>Academic Psychiatry</i> , 2007, 31, 218-224.	0.9	7
161	The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the Acute and Continuation Phases. <i>Biological Psychiatry</i> , 2007, 62, 1371-1379.	1.3	39
162	Tiagabine for social anxiety disorder. <i>Human Psychopharmacology</i> , 2007, 22, 241-244.	1.5	33

#	ARTICLE	IF	CITATIONS
163	Relative risk of glucose elevation during antipsychotic exposure in a Veterans Administration population. <i>International Clinical Psychopharmacology</i> , 2007, 22, 1-11.	1.7	24
164	Psychosocial context of antidepressant response. <i>Biological Psychiatry</i> , 2005, 57, 314.	1.3	0
165	Commentary. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2005, 7, 300-3.	0.6	1
166	Disturbed glucose metabolism among patients taking olanzapine and typical antipsychotics. <i>Psychopharmacology Bulletin</i> , 2003, 37, 99-117.	0.0	8
167	Assessment of human exposure and human health effects after indoor application of methyl parathion in Lorain County, Ohio, 1995-1996.. <i>Environmental Health Perspectives</i> , 2002, 110, 1047-1051.	6.0	33